Brief: Celyad Oncology Says FY Loss Per Share EUR 1.23
24/03/2021 20:14
March 24 (Reuters) - Celyad Oncology CYAD.BR :
* FY NET LOSS -17.2 MILLION EUR VERSUS -28.6 MILLION EUR
LOSS YEAR
AGO
* FY LOSS PER SHARE 1.23 EUR VERSUS 2.29 EUR LOSS YEAR AGO
* CELYAD - ON TRACK TO INITIATE PHASE 1B KEYNOTE-B79 TRIAL
EVALUATING CYAD-101 WITH KEYTRUDA IN PATIENTS WITH
MICROSATELLITE STABLE MCRC IN H1 2021
* CELYAD- NO SAFETY CONCERNS OR EVIDENCE OF
GRAFT-VERSUS-HOST
DISEASE REPORTED FROM FIRST DOSE COHORT OF PHASE1
DOSE-ESCALATION IMMUNICY1 TRIAL
* ADDITIONAL DATA FROM DOSE LEVEL 3 OF PHASE 1 CYCLE-1 TRIAL
OF
CYAD-02 FOR R/R AML AND MDS ARE ANTICIPATED IN FIRST HALF OF
2021
* CELYAD- ADDITIONAL PROOF-OF-CONCEPT DATA FROM INITIAL DOSE
COHORTS OF PHASE 1 IMMUNICY-1 TRIAL OF CYAD-211 FOR R/R MM
EXPECTED END OF Q2 2021
Source text for Eikon: ID:nBw2VSWXKa
Further company coverage: CYAD.BR
((Reuters.Briefs@thomsonreuters.com;))